Story perspectives

FDA Warns Novo Nordisk Over Ozempic and Wegovy Reporting Issues

3/18/2026

Summary

Story summary

The U.S. Food and Drug Administration warned Novo Nordisk about reporting adverse events tied to Ozempic and Wegovy, including deaths.
FDA contends Novo Nordisk failed to report severe health complications, raising monitoring concerns.
An analysis shows a spike in reports after an early-2025 inspection, with over 50,000 since 2020 and at least 600 deaths.
Novo Nordisk maintains safety confidence and is improving reporting procedures, while facing lawsuits alleging inadequate warnings.

1 of 1

Story summary

The U.S. Food and Drug Administration warned Novo Nordisk about reporting adverse events tied to Ozempic and Wegovy, including deaths.
FDA contends Novo Nordisk failed to report severe health complications, raising monitoring concerns.
An analysis shows a spike in reports after an early-2025 inspection, with over 50,000 since 2020 and at least 600 deaths.
Novo Nordisk maintains safety confidence and is improving reporting procedures, while facing lawsuits alleging inadequate warnings.